IC
FLGT icon

Inscription Capital’s Fulgent Genetics FLGT Stock Holding History

Inscription Capital’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$210K Sell
10,252
-2,143
-17% -$36.3K 0.02% 683
2026
Q1 		$197K Buy
+12,395
New +$269K 0.02% 627

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Inscription Capital's FLGT Position: Q2 2026 in Review

Inscription Capital reduced its Fulgent Genetics (FLGT) stake by 17% in Q2 2026, selling an estimated $36.3K and leaving 10,252 shares worth $210K. The position accounts for 0.02% of the portfolio, ranked #683.

Inscription Capital first reported a position in FLGT in Q1 2026 and has held it in 2 quarters since. 142 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • Inscription Capital held 10,252 shares of Fulgent Genetics worth $210K as of Q2 2026.
  • Inscription Capital sold 2,143 Fulgent Genetics shares in Q2 2026, an estimated $36.3K.
  • Fulgent Genetics made up 0.02% of Inscription Capital's portfolio in Q2 2026, its #683 holding.
  • Inscription Capital first reported a position in Fulgent Genetics in Q1 2026 and has held it in 2 quarters since.
  • 142 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on Inscription Capital's 13F filing for Q2 2026, filed 13 Aug 2026.